Why should I order ImpriMed services?

ImpriMed offers a unique precision oncology service that helps you to find the best anticancer drugs for your patients.ImpriMed directly tests a panel of commonly used anticancer drugs on your patients’ live cells in our A2LA accredited lab.In addition, we continually collect patient outcomes that are updated via regular follow-up with pet parents.As our database grows, so does the performance of our anticancer drug response predictions and your ability to develop a personalized treatment plan for each pet patient.So, when you order an ImpriMed service, you are actively contributing to our dataset and helping to improve cancer care for your patients and the ImpiMed user community.

Other Questions

Back to Help Center

Does the ordering veterinarian have to be an oncologist?

No, any licensed veterinarian can order all ImpriMed's services.

Read More

For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Read More

Do you test "rescue" drugs as well?

Yes, many of the 13 anticancer drugs we provide predictions for are used for rescue therapy. The drugs we test against are: L-Asparaginase, Mitoxantrone, Vincristine, Vinblastine, Doxorubicin, Tanovea, Chlorambucil, Mechlorethamine, Lomustine, Prednisone, Cyclophosphamide, Melphalan, and Dexamethasone.

Read More

Can we select non-MDR substrate drugs for known or suspected MDR dogs?

Yes, you can select non-MDR1 drugs when indicating your drug priorities, but the final report will also include all drugs.

Read More

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.

Read More